Plain-English translation of NCT04743518 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
People with ulcerative colitis have a higher risk of heart disease than the general population. This trial is testing how three different medications—infliximab, adalimumab, golimumab, vedolizumab, and tofacitinib—affect blood vessel health and cardiovascular risk. Researchers want to understand whether the medication you start affects your heart differently over time.
While we know these medications work well for treating bowel inflammation, we don't yet know how each one impacts your long-term heart and blood vessel health. This study will help doctors choose the safest medications for patients who have both ulcerative colitis and heart disease risk.
You likely qualify if…
You likely don't qualify if…
You will start one of the study medications as your regular bowel disease treatment. You'll visit the clinic at the beginning, after 3 months, and after 12 months. At each visit, researchers will perform non-invasive heart tests (including ultrasound of your blood vessels) and blood tests to measure inflammation and heart health markers. The entire study lasts one year.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France
Phase
Post-approval monitoring
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment target
~100 participants
Started
February 2021
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mathurin Fumery, Pr
Centre Hospitalier Universitaire, Amiens
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.